BR112022016675A2 - Compostos para uso em condições inflamatórias - Google Patents

Compostos para uso em condições inflamatórias

Info

Publication number
BR112022016675A2
BR112022016675A2 BR112022016675A BR112022016675A BR112022016675A2 BR 112022016675 A2 BR112022016675 A2 BR 112022016675A2 BR 112022016675 A BR112022016675 A BR 112022016675A BR 112022016675 A BR112022016675 A BR 112022016675A BR 112022016675 A2 BR112022016675 A2 BR 112022016675A2
Authority
BR
Brazil
Prior art keywords
compounds
inflammatory conditions
inflammation
relates
toll
Prior art date
Application number
BR112022016675A
Other languages
English (en)
Inventor
Avilés Marín Pablo
Losada González Alejandro
María Fernández Sousa-Faro José
Fudio Muñoz Salvador
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of BR112022016675A2 publication Critical patent/BR112022016675A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSTOS PARA USO EM CONDIÇÕES INFLAMATÓRIAS. A presente invenção refere-se ao uso de compostos no tratamento de inflamação, preferivelmente inflamação associada à ativação de receptores do tipo Toll. A invenção refere-se também ao uso de compostos para tratar inflamação induzida por patógenos.
BR112022016675A 2020-03-02 2021-03-02 Compostos para uso em condições inflamatórias BR112022016675A2 (pt)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
EP20382152 2020-03-02
EP20382192 2020-03-13
EP20382266 2020-04-02
EP20382339 2020-04-27
EP20382815 2020-09-16
EP20382816 2020-09-16
EP21382059 2021-01-25
PCT/EP2021/055187 WO2021175857A1 (en) 2020-03-02 2021-03-02 Compounds for use in inflammatory conditions

Publications (1)

Publication Number Publication Date
BR112022016675A2 true BR112022016675A2 (pt) 2022-10-11

Family

ID=74732953

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112022016604A BR112022016604A2 (pt) 2020-03-02 2021-03-02 Compostos para uso em infecções virais
BR112022016675A BR112022016675A2 (pt) 2020-03-02 2021-03-02 Compostos para uso em condições inflamatórias

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112022016604A BR112022016604A2 (pt) 2020-03-02 2021-03-02 Compostos para uso em infecções virais

Country Status (16)

Country Link
US (2) US20230295236A1 (pt)
EP (2) EP4114435A1 (pt)
JP (2) JP2023517535A (pt)
KR (2) KR20220151643A (pt)
CN (2) CN115461067A (pt)
AU (2) AU2021232535A1 (pt)
BR (2) BR112022016604A2 (pt)
CA (2) CA3169540A1 (pt)
CL (2) CL2022002396A1 (pt)
CO (2) CO2022014031A2 (pt)
IL (2) IL296068A (pt)
MX (2) MX2022010926A (pt)
PE (2) PE20230606A1 (pt)
TW (2) TW202146038A (pt)
UY (2) UY39109A (pt)
WO (2) WO2021175857A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024165764A1 (en) * 2023-02-10 2024-08-15 Pharma Mar, S.A. Plitidepsin for use in the treatment of non-integrated dna viral infections
CN117285611B (zh) * 2023-11-24 2024-02-09 中国海洋大学 一种来源于海鞘的抗炎寡肽及其在制备药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8922026D0 (en) * 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
US6156724A (en) * 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
MXPA02009943A (es) 2000-04-07 2003-04-25 Univ Pennsylvania Analogos de tamandarin y didemnin y metodos para hacerlos y usarlos.
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
JP2006523214A (ja) 2003-03-21 2006-10-12 ジユーリー，マデレーン・エム タマンダリン類似物およびこれらのフラグメントそして製造方法および使用方法
WO2011020913A2 (en) 2009-08-21 2011-02-24 Pharma Mar, S.A. Cyclodepsipeptide antiviral compounds

Also Published As

Publication number Publication date
JP2023517535A (ja) 2023-04-26
CN115666616A (zh) 2023-01-31
US20230159594A1 (en) 2023-05-25
KR20220151643A (ko) 2022-11-15
CO2022014031A2 (es) 2022-10-21
KR20220150350A (ko) 2022-11-10
MX2022010921A (es) 2022-09-29
CL2022002396A1 (es) 2023-06-30
WO2021175831A3 (en) 2021-10-14
PE20230606A1 (es) 2023-04-10
AU2021231197A1 (en) 2022-10-06
EP4114433A2 (en) 2023-01-11
EP4114435A1 (en) 2023-01-11
TW202146038A (zh) 2021-12-16
IL296069A (en) 2022-11-01
CA3169544A1 (en) 2021-09-10
UY39110A (es) 2021-09-30
UY39109A (es) 2021-09-30
WO2021175831A2 (en) 2021-09-10
MX2022010926A (es) 2022-09-29
WO2021175857A1 (en) 2021-09-10
US20230295236A1 (en) 2023-09-21
CN115461067A (zh) 2022-12-09
PE20230412A1 (es) 2023-03-07
AU2021232535A1 (en) 2022-10-06
CA3169540A1 (en) 2021-09-10
CL2022002395A1 (es) 2023-06-30
BR112022016604A2 (pt) 2022-10-11
TW202144381A (zh) 2021-12-01
CO2022014093A2 (es) 2022-11-18
JP2023517536A (ja) 2023-04-26
IL296068A (en) 2022-11-01

Similar Documents

Publication Publication Date Title
BR112016009047A2 (pt) Uso de moléculas de ligação à semaforina-4d para tratar transtornos neurodegenerativos
CL2018002703A1 (es) Agentes de iarn, composiciones y métodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr). (divisional solicitud 201401291)
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
BR112022016675A2 (pt) Compostos para uso em condições inflamatórias
CR20150054A (es) Anticuerpos anti-cxcr5 humanizados derivados de los mismos y su uso
CL2017001924A1 (es) Anticuerpos anti-transtiretina
CR20140223A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
CL2015002485A1 (es) Uso de agonistas de receptor de péptido formilo 2 para tratar enfermedades inflamatorias oculares
CL2007001670A1 (es) Uso de compuestos derivados de amina para el tratamiento de un trastorno mediado por citoquinas.
BR112016026993A2 (pt) combinação de um anticorpo anti-ccr4 e um agonista 4-1bb para tratar câncer
CU20140073A7 (es) Composiciones y métodos para anticuerpos que actúan sobre el factor p
CO2017008482A2 (es) Anticuerpos anti-transtiretina
TR201906779T4 (tr) Proteostaz regülatörleri.
CR20160047A (es) Inhibidores de rorc2 y sus métodos de uso
BR112021025537A2 (pt) Azacitidina em combinação com venetoclax, gilteritinibe, midostaurina ou outros compostos para o tratamento de leucemia ou síndrome mielodisplásica
CO2021017688A2 (es) Anticuerpo biespecífico contra α-syn/igf1r y uso del mismo
BR112014000634A2 (pt) métodos para tratamento de incontinência associada com atividade sexual
BR112019009656A2 (pt) copolímeros diblocos automontados compostos por pegmema e segmentos poliméricos contendo fármacos
BR112018008900A8 (pt) composições compreendendo anticorpos para il6r para o tratamento de uveíte e edema macular e métodos de uso das mesmas
CR20150496A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
CL2022002589A1 (es) Tratamiento de trastornos respiratorios
BR112015024625A2 (pt) composição de galacto-oligossacarídeo para o uso na prevenção ou tratamento de disfunção cognitiva e transtornos emocionais em doenças neuropsiquiátricas ou envelhecimento
BR112019023742A2 (pt) anticorpos anti-trkb
CL2008000090A1 (es) Compuestos derivados de piridina; composicion farmaceutica que comprende a dichos compuestos; y su uso como inhibidores del receptor p2y 12 para tratar un trastorno de agragacion de plaquetas.
BR112019000635A2 (pt) inibidor de receptor 2 do tipo toll (tlr2) e seu uso, anticorpo, composição e método para tratar uma afecção inflamatória